162 related articles for article (PubMed ID: 37856922)
1. Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
Schmalz L; Bloomer C; Zhang W; Petty W
Lung Cancer; 2023 Dec; 186():107400. PubMed ID: 37856922
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z
Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189
[TBL] [Abstract][Full Text] [Related]
3. The development of amivantamab for the treatment of non-small cell lung cancer.
Brazel D; Nagasaka M
Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
[TBL] [Abstract][Full Text] [Related]
4. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
6. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Shah MP; Neal JW
Drugs; 2022 Apr; 82(6):649-662. PubMed ID: 35412115
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
8. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Gao J; Li HR; Jin C; Jiang JH; Ding JY
Clin Transl Oncol; 2019 Oct; 21(10):1287-1301. PubMed ID: 30864018
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
10. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
11. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
Oxnard GR; Arcila ME; Chmielecki J; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2011 Sep; 17(17):5530-7. PubMed ID: 21775534
[TBL] [Abstract][Full Text] [Related]
12. Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.
Kang J; Deng QM; Feng W; Chen ZH; Su JW; Chen HJ; Wang WX; Zhang S; Wang Q; Chen Z; Zhong WZ; Xu CW; Yang JJ
Lung Cancer; 2023 Apr; 178():66-74. PubMed ID: 36806896
[TBL] [Abstract][Full Text] [Related]
13. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
14. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
Ahn MJ; Mendoza MJL; Pavlakis N; Kato T; Soo RA; Kim DW; Liam CK; Hsia TC; Lee CK; Reungwetwattana T; Geater S; Chan OSH; Prasongsook N; Solomon BJ; Nguyen TTH; Kozuki T; Yang JC; Wu YL; Mok TSK; Tan DS; Yatabe Y
Clin Lung Cancer; 2022 Dec; 23(8):670-685. PubMed ID: 36151006
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
[TBL] [Abstract][Full Text] [Related]
16. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer.
Mi J; Huang Z; Zhang R; Zeng L; Xu Q; Yang H; Lizaso A; Tong F; Dong X; Yang N; Zhang Y
ESMO Open; 2022 Feb; 7(1):100347. PubMed ID: 34953403
[TBL] [Abstract][Full Text] [Related]
18. New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.
Girard N
Curr Treat Options Oncol; 2022 Nov; 23(11):1626-1644. PubMed ID: 36242712
[TBL] [Abstract][Full Text] [Related]
19. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
[TBL] [Abstract][Full Text] [Related]
20. Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.
Zheng J; Dou Y; Huang D; Wang Y; Han R; Hu C; Zhu M; Lu C; Lin C; Wu D; Liu Y; Tang H; He T; Jiang W; He Y
Jpn J Clin Oncol; 2024 Jan; 54(1):89-96. PubMed ID: 37721193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
